Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab for active Graves' orbitopathy poorly responsive to steroids
2012-001980-53Phase 3Active
- Sponsor
- Policlinico di Milano
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in Graves' ophthalmopathy (TED) and Graves Orbitopathy (GO), sponsored by Policlinico di Milano. Started Jun 2012; status: active.
02
Drugs
rituximab
03
Conditions
Graves' ophthalmopathy (TED)Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2012-001980-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001980-53.